Name: Vatalanib
Type: small molecule
Groups: investigational
Indication: Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).
Accession Number: DB04879 ( DB04879)
Description: Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.
Prescription Products: Not Available
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients

  • Antineoplastic Agents
  • Protein Kinase Inhibitors


Indication: Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).
Pharmacodynamics: Not Available
Mechanism of action: Vatalanib potently inhibits vascular endothelial growth factor (VEGF) receptor tyrosine kinases, important enzymes in the formation of new blood vessels that contribute to tumor growth and metastasis.
Absorption: Rapid onset of absorption
Volume of distribution: Not Available
Protein binding: Not Available
Metabolism: Not Available
Route of elimination: Not Available
Half life: Approximately 6 hours.
Clearance: Not Available
Toxicity: Not Available
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available


  • Not Available

  • Not Available

Dosage forms

Unit descriptionCostUnit

CountryPatent NumberApprovedExpires (estimated)


Drug Interactions

Food Interactions:
  • Not Available


Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Aminopyridazines
  • Aryl chlorides
  • Azacyclic compounds
  • Chlorobenzenes
  • Heteroaromatic compounds
  • Hydrocarbon derivatives
  • Imidolactams
  • Organochlorides
  • Pyridines and derivatives
  • Secondary amines

  • Amine
  • Aminopyridazine
  • Aromatic heteropolycyclic compound
  • Aryl chloride
  • Aryl halide
  • Azacycle
  • Benzenoid
  • Chlorobenzene
  • Halobenzene
  • Heteroaromatic compound
  • Hydrocarbon derivative
  • Imidolactam
  • Monocyclic benzene moiety
  • Organochloride
  • Organohalogen compound
  • Organonitrogen compound
  • Phthalazine
  • Pyridazine
  • Pyridine
  • Secondary amine


Synthesis Reference: Not Available
General Reference: # Yamamoto A, Watanabe H, Sueki H, Nakanishi T, Yasuhara H, Iijima M: Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity. J Dermatol. 2007 Jul;34(7):419-29. "Pubmed": # Lijnen HR, Van Hoef B, Kemp D, Collen D: Inhibition of vascular endothelial growth factor receptor tyrosine kinases impairs adipose tissue development in mouse models of obesity. Biochim Biophys Acta. 2007 Sep;1770(9):1369-73. Epub 2007 Jun 15. "Pubmed": # Jost LM, Gschwind HP, Jalava T, Wang Y, Guenther C, Souppart C, Rottmann A, Denner K, Waldmeier F, Gross G, Masson E, Laurent D: Metabolism and disposition of vatalanib (PTK787/ZK-222584) in cancer patients. Drug Metab Dispos. 2006 Nov;34(11):1817-28. Epub 2006 Aug 1. "Pubmed":
External Links:

ATC Codes:
  • Not Available

AHFS Codes:
  • Not Available

MSDS: Download

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.


The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.


Log in with your credentials

Forgot your details?